180 Life Sciences (NASDAQ:ATNF) Given “Sell (E+)” Rating at Weiss Ratings

180 Life Sciences (NASDAQ:ATNF)‘s stock had its “sell (e+)” rating reaffirmed by equities researchers at Weiss Ratings in a research report issued to clients and investors on Thursday,Weiss Ratings reports.

180 Life Sciences Stock Down 28.9%

ATNF opened at $7.61 on Thursday. The business has a fifty day moving average of $2.15 and a 200 day moving average of $1.46. The stock has a market cap of $45.96 million, a P/E ratio of -0.50 and a beta of 0.38. 180 Life Sciences has a 52-week low of $0.66 and a 52-week high of $17.75.

180 Life Sciences (NASDAQ:ATNF) last released its quarterly earnings data on Wednesday, July 23rd. The company reported ($0.30) EPS for the quarter.

Institutional Trading of 180 Life Sciences

An institutional investor recently bought a new position in 180 Life Sciences stock. Anson Funds Management LP purchased a new stake in 180 Life Sciences Corp. (NASDAQ:ATNF) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 225,271 shares of the company’s stock, valued at approximately $410,000. Anson Funds Management LP owned approximately 7.08% of 180 Life Sciences as of its most recent filing with the SEC. 4.07% of the stock is owned by institutional investors.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.